ClinicalTrials.gov
public full text
Public Domain
Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens
The purpose of this study is to assess the efficacy and safety of Apatinib combined with PD-1 antibody Sintilimab for for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer#1113867
- Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer#842059
- Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer#902647
- PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer#889180
- Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer#1351265
Record · ID 1280646
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive